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and long-term effects of rTMS in Alzheimer’s disease, we erro-
neously stated in our article (Lefaucheur et al., 2020) that a clinical
benefit on cognitive performance (tested by the Montreal Cogni-
tive Assessment) was observed at weeks 2–3, only in the real stim-
ulation condition during an initial sham-controlled 4-week period
of treatment, and that then this benefit was prolonged by ‘‘2 addi-
tional weeks” of open-label real rTMS. In fact, this extended open-
label treatment was administered for up to 19 months in multiple
2-week blocks with 2–7 months intervals between blocks and was
not limited to a single additional 2-week block of treatment imme-diately following the original 4 weeks of treatment. Therefore, the
results of that open-label extended follow-up study support the
value of long-term maintenance treatment using multiple rTMS
sessions rather than be interpreted as short-term 2-week
extension.
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